TY - JOUR
T1 - Temporal trends in heart failure medication prescription in a population-based cohort study
AU - Uijl, Alicia
AU - Vaartjes, Ilonca
AU - Denaxas, S
AU - Hemingway, Harry
AU - Shah, Anoop
AU - Cleland, J
AU - Grobbee, Diederick
AU - Hoes, Arno
AU - Asselbergs, Folkert W
AU - Koudstaal, Stefan
N1 - Funding Information:
Funding This study is part of the BigData@Heart program that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116074. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. This work was supported by Health Data Research UK [grant number N/A], which receives its funding from Health Data Research UK Ltd (NIWA1) funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and the Wellcome Trust. Work at the University College London Institute of Health Informatics and Institute of Cardiovascular Science is supported by a British Heart Foundation Accelerator Award (AA/18/6/24223). FA is supported by UCL Hospitals NIHR Biomedical Research Centre. IV is supported by a grant from the Dutch Heart Foundation [grant DHF project ‘Facts and Figures’]. SD is supported by an Alan Turing Fellowship. HH is supported by an NIHR Senior Investigator Award. ADS is funded by a post-doctoral fellowship from THIS Institute. JC received research grants from Bayer, Novartis and Vifor and honoraria for steering committees from Amgen, Bayer, Novartis and Servier.
Publisher Copyright:
© Author(s) (or their employer(s)) 2021.
PY - 2021/3/2
Y1 - 2021/3/2
N2 - OBJECTIVE: We examined temporal heart failure (HF) prescription patterns in a large representative sample of real-world patients in the UK, using electronic health records (EHR).METHODS: From primary and secondary care EHR, we identified 85 732 patients with a HF diagnosis between 2002 and 2015. Almost 50% of patients with HF were women and the median age was 79.1 (IQR 70.2-85.7) years, with age at diagnosis increasing over time.RESULTS: We found several trends in pharmacological HF management, including increased beta blocker prescriptions over time (29% in 2002-2005 and 54% in 2013-2015), which was not observed for mineralocorticoid receptor-antagonists (MR-antagonists) (18% in 2002-2005 and 18% in 2013-2015); higher prescription rates of loop diuretics in women and elderly patients together with lower prescription rates of angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers, beta blockers or MR-antagonists in these patients; little change in medication prescription rates occurred after 6 months of HF diagnosis and, finally, patients hospitalised for HF who had no recorded follow-up in primary care had considerably lower prescription rates compared with patients with a HF diagnosis in primary care with or without HF hospitalisation.CONCLUSION: In the general population, the use of MR-antagonists for HF remained low and did not change throughout 13 years of follow-up. For most patients, few changes were seen in pharmacological management of HF in the 6 months following diagnosis.
AB - OBJECTIVE: We examined temporal heart failure (HF) prescription patterns in a large representative sample of real-world patients in the UK, using electronic health records (EHR).METHODS: From primary and secondary care EHR, we identified 85 732 patients with a HF diagnosis between 2002 and 2015. Almost 50% of patients with HF were women and the median age was 79.1 (IQR 70.2-85.7) years, with age at diagnosis increasing over time.RESULTS: We found several trends in pharmacological HF management, including increased beta blocker prescriptions over time (29% in 2002-2005 and 54% in 2013-2015), which was not observed for mineralocorticoid receptor-antagonists (MR-antagonists) (18% in 2002-2005 and 18% in 2013-2015); higher prescription rates of loop diuretics in women and elderly patients together with lower prescription rates of angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers, beta blockers or MR-antagonists in these patients; little change in medication prescription rates occurred after 6 months of HF diagnosis and, finally, patients hospitalised for HF who had no recorded follow-up in primary care had considerably lower prescription rates compared with patients with a HF diagnosis in primary care with or without HF hospitalisation.CONCLUSION: In the general population, the use of MR-antagonists for HF remained low and did not change throughout 13 years of follow-up. For most patients, few changes were seen in pharmacological management of HF in the 6 months following diagnosis.
KW - cardiac epidemiology
KW - heart failure
KW - public health
UR - http://www.scopus.com/inward/record.url?scp=85102057328&partnerID=8YFLogxK
U2 - 10.1136/bmjopen-2020-043290
DO - 10.1136/bmjopen-2020-043290
M3 - Article
C2 - 33653753
SN - 2044-6055
VL - 11
SP - 1
EP - 9
JO - BMJ Open
JF - BMJ Open
IS - 3
M1 - e043290
ER -